19.81 USD
+0.23 (+1.17%)
Overall ADMA gets a fundamental rating of 7 out of 10. We evaluated ADMA against 530 industry peers in the Biotechnology industry. While ADMA has a great health rating, its profitability is only average at the moment. ADMA is not overvalued while it is showing excellent growth. This is an interesting combination. These ratings would make ADMA suitable for growth investing!
1. Profitability
1.1 Basic Checks
ADMA had positive earnings in the past year.
ADMA had a positive operating cash flow in the past year.
ADMA had negative earnings in 4 of the past 5 years.
In multiple years ADMA reported negative operating cash flow during the last 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of 36.83%, ADMA belongs to the top of the industry, outperforming 98.68% of the companies in the same industry.
With an excellent Return On Equity value of 48.57%, ADMA belongs to the best of the industry, outperforming 98.68% of the companies in the same industry.
With an excellent Return On Invested Capital value of 25.76%, ADMA belongs to the best of the industry, outperforming 98.68% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 36.83% | ||
| ROE | 48.57% | ||
| ROIC | 25.76% |
ROA(3y)4.32%
ROA(5y)-9.88%
ROE(3y)-2.53%
ROE(5y)-28.83%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With an excellent Profit Margin value of 42.87%, ADMA belongs to the best of the industry, outperforming 97.92% of the companies in the same industry.
The Operating Margin of ADMA (34.19%) is better than 97.36% of its industry peers.
The Gross Margin of ADMA (54.71%) is better than 76.79% of its industry peers.
In the last couple of years the Gross Margin of ADMA has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 34.19% | ||
| PM (TTM) | 42.87% | ||
| GM | 54.71% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y226.2%
GM growth 5YN/A
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so ADMA is creating value.
The number of shares outstanding for ADMA has been increased compared to 1 year ago.
ADMA has more shares outstanding than it did 5 years ago.
The debt/assets ratio for ADMA has been reduced compared to a year ago.
2.2 Solvency
ADMA has an Altman-Z score of 22.37. This indicates that ADMA is financially healthy and has little risk of bankruptcy at the moment.
ADMA's Altman-Z score of 22.37 is amongst the best of the industry. ADMA outperforms 90.94% of its industry peers.
ADMA has a debt to FCF ratio of 1.78. This is a very positive value and a sign of high solvency as it would only need 1.78 years to pay back of all of its debts.
ADMA's Debt to FCF ratio of 1.78 is amongst the best of the industry. ADMA outperforms 93.58% of its industry peers.
A Debt/Equity ratio of 0.16 indicates that ADMA is not too dependend on debt financing.
With a Debt to Equity ratio value of 0.16, ADMA is not doing good in the industry: 66.23% of the companies in the same industry are doing better.
Even though the debt/equity ratio score it not favorable for ADMA, it has very limited outstanding debt, so we won't put too much weight on the DE evaluation.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.16 | ||
| Debt/FCF | 1.78 | ||
| Altman-Z | 22.37 |
ROIC/WACC2.93
WACC8.79%
2.3 Liquidity
ADMA has a Current Ratio of 7.13. This indicates that ADMA is financially healthy and has no problem in meeting its short term obligations.
With a decent Current ratio value of 7.13, ADMA is doing good in the industry, outperforming 70.57% of the companies in the same industry.
ADMA has a Quick Ratio of 3.65. This indicates that ADMA is financially healthy and has no problem in meeting its short term obligations.
ADMA's Quick ratio of 3.65 is in line compared to the rest of the industry. ADMA outperforms 46.23% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 7.13 | ||
| Quick Ratio | 3.65 |
3. Growth
3.1 Past
ADMA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 92.86%, which is quite impressive.
ADMA shows a strong growth in Revenue. In the last year, the Revenue has grown by 27.62%.
The Revenue has been growing by 70.84% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)92.86%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)27.62%
Revenue growth 3Y74.04%
Revenue growth 5Y70.84%
Sales Q2Q%12%
3.2 Future
ADMA is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 33.90% yearly.
ADMA is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 21.48% yearly.
EPS Next Y19.68%
EPS Next 2Y36.5%
EPS Next 3Y36.8%
EPS Next 5Y33.9%
Revenue Next Year20.91%
Revenue Next 2Y22.61%
Revenue Next 3Y24.25%
Revenue Next 5Y21.48%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
ADMA is valuated quite expensively with a Price/Earnings ratio of 36.69.
ADMA's Price/Earnings ratio is rather cheap when compared to the industry. ADMA is cheaper than 91.51% of the companies in the same industry.
ADMA's Price/Earnings ratio indicates a valuation a bit more expensive than the S&P500 average which is at 26.39.
The Price/Forward Earnings ratio is 21.26, which indicates a rather expensive current valuation of ADMA.
Compared to the rest of the industry, the Price/Forward Earnings ratio of ADMA indicates a rather cheap valuation: ADMA is cheaper than 94.34% of the companies listed in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 23.84. ADMA is around the same levels.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 36.69 | ||
| Fwd PE | 21.26 |
4.2 Price Multiples
93.02% of the companies in the same industry are more expensive than ADMA, based on the Enterprise Value to EBITDA ratio.
91.13% of the companies in the same industry are more expensive than ADMA, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 116.1 | ||
| EV/EBITDA | 26.69 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
The decent profitability rating of ADMA may justify a higher PE ratio.
ADMA's earnings are expected to grow with 36.80% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.86
PEG (5Y)N/A
EPS Next 2Y36.5%
EPS Next 3Y36.8%
5. Dividend
5.1 Amount
No dividends for ADMA!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
NASDAQ:ADMA (12/22/2025, 2:42:33 PM)
19.81
+0.23 (+1.17%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners93.44%
Inst Owner Change5.68%
Ins Owners2.35%
Ins Owner Change-0.61%
Market Cap4.71B
Revenue(TTM)488.56M
Net Income(TTM)209.45M
Analysts84
Price Target27.8 (40.33%)
Short Float %8.12%
Short Ratio5.4
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-1.96%
Min EPS beat(2)-1.96%
Max EPS beat(2)-1.96%
EPS beat(4)0
Avg EPS beat(4)-10.9%
Min EPS beat(4)-31.17%
Max EPS beat(4)-1.96%
EPS beat(8)3
Avg EPS beat(8)-42.78%
EPS beat(12)6
Avg EPS beat(12)-7.71%
EPS beat(16)8
Avg EPS beat(16)-5.59%
Revenue beat(2)1
Avg Revenue beat(2)-0.85%
Min Revenue beat(2)-2.51%
Max Revenue beat(2)0.81%
Revenue beat(4)2
Avg Revenue beat(4)-0.71%
Min Revenue beat(4)-3.31%
Max Revenue beat(4)2.16%
Revenue beat(8)6
Avg Revenue beat(8)4.26%
Revenue beat(12)10
Avg Revenue beat(12)4.8%
Revenue beat(16)14
Avg Revenue beat(16)6.2%
PT rev (1m)0%
PT rev (3m)-6.23%
EPS NQ rev (1m)0%
EPS NQ rev (3m)5.66%
EPS NY rev (1m)-1.12%
EPS NY rev (3m)2.48%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)1.84%
Revenue NY rev (1m)0.92%
Revenue NY rev (3m)0.92%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 36.69 | ||
| Fwd PE | 21.26 | ||
| P/S | 9.65 | ||
| P/FCF | 116.1 | ||
| P/OCF | 72.57 | ||
| P/B | 10.93 | ||
| P/tB | 11.04 | ||
| EV/EBITDA | 26.69 |
EPS(TTM)0.54
EY2.73%
EPS(NY)0.93
Fwd EY4.7%
FCF(TTM)0.17
FCFY0.86%
OCF(TTM)0.27
OCFY1.38%
SpS2.05
BVpS1.81
TBVpS1.79
PEG (NY)1.86
PEG (5Y)N/A
Graham Number4.69
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 36.83% | ||
| ROE | 48.57% | ||
| ROCE | 32.61% | ||
| ROIC | 25.76% | ||
| ROICexc | 29.27% | ||
| ROICexgc | 29.53% | ||
| OM | 34.19% | ||
| PM (TTM) | 42.87% | ||
| GM | 54.71% | ||
| FCFM | 8.31% |
ROA(3y)4.32%
ROA(5y)-9.88%
ROE(3y)-2.53%
ROE(5y)-28.83%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y226.2%
GM growth 5YN/A
F-Score7
Asset Turnover0.86
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.16 | ||
| Debt/FCF | 1.78 | ||
| Debt/EBITDA | 0.4 | ||
| Cap/Depr | 304.79% | ||
| Cap/Sales | 4.99% | ||
| Interest Coverage | 15.23 | ||
| Cash Conversion | 37.13% | ||
| Profit Quality | 19.39% | ||
| Current Ratio | 7.13 | ||
| Quick Ratio | 3.65 | ||
| Altman-Z | 22.37 |
F-Score7
WACC8.79%
ROIC/WACC2.93
Cap/Depr(3y)120.67%
Cap/Depr(5y)186.15%
Cap/Sales(3y)4.32%
Cap/Sales(5y)11.97%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)92.86%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y19.68%
EPS Next 2Y36.5%
EPS Next 3Y36.8%
EPS Next 5Y33.9%
Revenue 1Y (TTM)27.62%
Revenue growth 3Y74.04%
Revenue growth 5Y70.84%
Sales Q2Q%12%
Revenue Next Year20.91%
Revenue Next 2Y22.61%
Revenue Next 3Y24.25%
Revenue Next 5Y21.48%
EBIT growth 1Y45.36%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year63.58%
EBIT Next 3Y47.86%
EBIT Next 5Y37.89%
FCF growth 1Y272.8%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y501.56%
OCF growth 3YN/A
OCF growth 5YN/A
ADMA BIOLOGICS INC / ADMA FAQ
What is the fundamental rating for ADMA stock?
ChartMill assigns a fundamental rating of 7 / 10 to ADMA.
Can you provide the valuation status for ADMA BIOLOGICS INC?
ChartMill assigns a valuation rating of 6 / 10 to ADMA BIOLOGICS INC (ADMA). This can be considered as Fairly Valued.
How profitable is ADMA BIOLOGICS INC (ADMA) stock?
ADMA BIOLOGICS INC (ADMA) has a profitability rating of 6 / 10.
What are the PE and PB ratios of ADMA BIOLOGICS INC (ADMA) stock?
The Price/Earnings (PE) ratio for ADMA BIOLOGICS INC (ADMA) is 36.69 and the Price/Book (PB) ratio is 10.93.
Can you provide the financial health for ADMA stock?
The financial health rating of ADMA BIOLOGICS INC (ADMA) is 8 / 10.